BB Biotech Reports Strong Preliminary 2025 Results and Dividend Proposal

BB Biotech AG has released its preliminary and unaudited financial results for 2025. The company reported a solid performance, with shares showing a total return of +34.2% in CHF, +37.0% in EUR, and +53.7% in USD. This performance surpasses the Nasdaq Biotechnology Index's gain of +33.4% in USD, demonstrating a share price outperformance of +20.3% in USD. The net profit for the year reached CHF 578 million, a significant increase from CHF 76 million in 2024.

In the fourth quarter of 2025, BB Biotech shares achieved a total return of +24.0% in CHF, outperforming the sector index. The company also reported a quarterly net profit of CHF 472 million, compared to CHF 60 million in Q4 2024. The share price closed 2025 at a 10.8% discount to NAV, a notable improvement from 15.2% at the end of 2024.

The Board of Directors will propose a dividend of CHF 2.25 per share at the upcoming Annual General Meeting. This proposal aligns with BB Biotech's long-term investment and shareholder return strategy.